Halozyme Therapeutics, Inc. (LON:0J2O)
London · Delayed Price · Currency is GBP · Price in USD 77.11
-2.98 (-3.72%)
Feb 12, 2026, 5:07 PM GMT
Halozyme Therapeutics Market Cap
Halozyme Therapeutics has a market cap or net worth of 6.85 billion as of February 12, 2026. Its market cap has increased by 19.62% in one year.
Market Cap
6.85B
Enterprise Value
7.47B
Revenue
924.61M
Ranking
n/a
PE Ratio
15.47
Stock Price
77.11
Market Cap Chart
Since May 14, 2004, Halozyme Therapeutics's market cap has increased from 95.57M to 6.85B, an increase of 7,070.49%. That is a compound annual growth rate of 21.69%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 11, 2026 | 6.85B | 16.54% |
| Dec 31, 2025 | 5.88B | 21.03% |
| Dec 31, 2024 | 4.86B | 26.76% |
| Dec 29, 2023 | 3.83B | -39.97% |
| Dec 30, 2022 | 6.39B | 52.80% |
| Dec 31, 2021 | 4.18B | -1.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca | 229.82B |
| GSK plc | 87.00B |
| Haleon | 36.19B |
| Smith & Nephew | 10.94B |
| Convatec Group | 4.29B |
| Hikma Pharmaceuticals | 3.44B |
| Genus | 2.09B |
| HUTCHMED (China) | 1.88B |